Kathleen A. McGowan, Chief Financial Officer
Kathleen McGowan joined VaxInnate as Chief Financial Officer in January 2013. Kathleen brings 30 years of diversified financial experience in the pharmaceutical and biotech industry. From 2008-12 she served as the Vice President, Finance, at Tobira, a privately-held biopharmaceutical company developing innovative therapies for treatment of HIV infection. Prior to Tobira, she was Director, Finance and Controller (Chief Accounting Officer) for Discovery Laboratories, Inc., a publicly-held biotech company focused on advancing respiratory critical care. From 2000-04, Kathleen served as Director of Financial Analysis at Claneil Enterprises, Inc., a private equity investment firm. Previously, she served as Financial Controller at The Liposome Company, Inc., a publicly-held biotech company acquired by Elan Corporation, plc, and was Controller at Nelson Communications. From 1983-1995, Kathleen held various financial management positions with Johnson & Johnson, primarily at Ortho-McNeil Pharmaceutical and Johnson & Johnson Corporate. Kathleen received her Bachelor of Science degree in Finance and Accounting from Drexel University and holds an M.B.A. in Finance from Fairleigh Dickinson University.